Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Ocugen stock

Learn how to easily invest in Ocugen stock.

Ocugen is a biotechnology business based in the US. Ocugen shares (OCGN) are listed on the NASDAQ and all prices are listed in US Dollars. Ocugen employs 56 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Ocugen stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – OCGN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Ocugen stock price (NASDAQ: OCGN)

Use our graph to track the performance of OCGN stocks over time.

Ocugen shares at a glance

Information last updated 2023-02-01.
Latest market close$1.24
52-week range$1.09 - $4.53
50-day moving average $1.37
200-day moving average $2.02
Wall St. target price$5.33
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.35

Buy Ocugen stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Ocugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ocugen price performance over time

Historical closes compared with the close of $1.24 from 2023-02-07

1 week (2023-02-01) -2.36%
1 month (2023-01-06) -4.62%
3 months (2022-11-08) -24.39%
6 months (2022-08-08) -56.49%
1 year (2022-02-04) -65.46%
2 years (2021-02-08) -92.16%
3 years (2020-02-07) 142.80%
5 years (2018-02-08) 154.2

Ocugen financials

Gross profit TTM $-35,108,000
Return on assets TTM -40.47%
Return on equity TTM -73.11%
Profit margin 0%
Book value $0.44
Market capitalisation $278 million

TTM: trailing 12 months

Ocugen share dividends

We're not expecting Ocugen to pay a dividend over the next 12 months.

Have Ocugen's shares ever split?

Ocugen's shares were split on a 1:60 basis on 29 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.

Ocugen share price volatility

Over the last 12 months, Ocugen's shares have ranged in value from as little as $1.09 up to $4.53. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocugen's is 3.8845. This would suggest that Ocugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Ocugen overview

Ocugen, Inc. , a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Frequently asked questions

What percentage of Ocugen is owned by insiders or institutions?
Currently 2.476% of Ocugen shares are held by insiders and 37.871% by institutions.
How many people work for Ocugen?
Latest data suggests 56 work at Ocugen.
When does the fiscal year end for Ocugen?
Ocugen's fiscal year ends in December.
Where is Ocugen based?
Ocugen's address is: 263 Great Valley Parkway, Malvern, PA, United States, 19355
What is Ocugen's ISIN number?
Ocugen's international securities identification number is: US67577C1053
What is Ocugen's CUSIP number?
Ocugen's Committee on Uniform Securities Identification Procedures number is: 67577C105

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site